LAUSR

development of such policies and practices for product infusion and adverse event management should be a multidisciplinary undertaking, as these boutique products are used in highly specialized care areas where the expertise of our colleagues is invaluable. As the field of immunotherapies derived from autologous blood product donations continues to expand, these products necessitate a new approach for proper management rather than reliance on existing blood product practices and procedures. As these products are very similar to traditional hematopoietic progenitor cell products with regard to regulatory standards and workflow, dispensation by Cellular Therapy may be more appropriate in many cases. The unique expertise in transfusion medicine of proper management and handling for a variety of biologic products of human origin makes this an ideal opportunity to develop more applicable standard operating procedures as we continue to race into the future of blood banking and personalized medicine.